Study Protocol for MS tolDC: a phase I clinical trial of a personalized 'Negative' dendritic cell-based vaccine for the treatment of multiple sclerosis

B. Willekens, J. Derdelinckx, P. Cras, P. Parizel, E. Martinez-Caceres, C. Ramo-Tello, W. Van Hecke, A. Ribbens, Z. Berneman, N. Cools

Research output: Contribution to journalAbstract/Meeting Abstract

Original languageEnglish
Pages (from-to)777-777
Number of pages1
JournalMultiple Sclerosis Journal
Volume22
Publication statusPublished - Sep 2016
Externally publishedYes
Event32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) - London
Duration: 14 Sep 201617 Sep 2016

Cite this

Willekens, B., Derdelinckx, J., Cras, P., Parizel, P., Martinez-Caceres, E., Ramo-Tello, C., Van Hecke, W., Ribbens, A., Berneman, Z., & Cools, N. (2016). Study Protocol for MS tolDC: a phase I clinical trial of a personalized 'Negative' dendritic cell-based vaccine for the treatment of multiple sclerosis. Multiple Sclerosis Journal, 22, 777-777.